News | March 20, 2025
Briefs: Dr. Agarwal's Eye Hospital and Apitoria Pharma
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
The new lenders – JP Morgan, HSBC, and Barclays provided fresh funding
The recent EU approval of MBL's plant has opened new avenues to explore such opportunities
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Subscribe To Our Newsletter & Stay Updated
